<DOC>
	<DOCNO>NCT02267512</DOCNO>
	<brief_summary>To investigate efficacy safety ATG-F induction regimen use single dose ATG-F compare five-day dose regimen ATG-F anew kidney transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Two Anti-T-lymphocyte Immune Globulin ( ATG-F ) Induction Regimens Anew Kidney Transplant Patients</brief_title>
	<detailed_description>To investigate efficacy safety ATG-F induction regimen use single dose ATG-F compare five-day dose regimen ATG-F de novo kidney transplant recipient . The primary analysis study demonstrate non-inferiority two regimen regard efficacy , defined failure rate . The secondary objective study assessment safety efficacy parameter term incidence acute rejection , graft/patient survival , DGF ( delay graft function ) renal function</detailed_description>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Patient end stage kidney disease suitable candidate primary kidney transplantation . Patients schedule undergo renal allograft transplantation compatible ABO blood type . Peak PRA &lt; 50 % Females childbearing potential must negative pregnancy test within 48hrs prior randomization reliable method contraception start 4 week prior whole study . Patients capable understand purpose risk study , willing able participate study write date informed consent participate study obtain . Subject previously receive receive organ transplant kidney Subject receive doublekidney transplant . Subject receive ABO incompatible Tcells cross match positive transplant . Cold ischemia time allograft &gt; 24 hour kidney transplantation surgery . Subject receive organ Human Leukocyte Antibody ( HLA ) identical donor . Known contraindication administration ATGF , include : Subject know hypersensitivity rabbit protein Subject severe thrombocytopenia Subject bacterial , viral mycotic infection therapeutically control Subject know hypersensitivity tacrolimus , macrolide antibiotic , mycophenolate mofetil , product excipients . Subject unlikely comply visit schedule protocol opinion investigator history noncompliance . Pregnant woman , nurse mother , lactate woman , woman childbearing potential unwilling use reliable contraception study 6 week follow completion study . Patients evidence active liver disease ( liver function test â‰¥ 2 time upper limit normal ) presence chronic active hepatitis B C. Recipient donor seropositive human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kidney Transplant Patients</keyword>
	<keyword>ATG-F</keyword>
</DOC>